Federal health advisers have endorsed a new blood test by Grail Inc., called the Galleri test, which aims to detect signs of various cancers in seemingly healthy individuals. This test, which analyzes DNA from a single blood draw, does not diagnose cancer but signals the potential presence of tumors, requiring further medical evaluation for confirmation. The advisory panel voted 7-2 in favor of the test, acknowledging its potential benefits despite uncertainties about its effectiveness. The test is currently available for purchase, but FDA approval could lead to broader access through insurance coverage. While the test could revolutionize early cancer detection, experts caution it should complement, not replace, existing screenings like mammograms. Concerns remain about its accuracy, particularly in detecting early-stage cancers, and the risk of false positives or negatives. The FDA’s final decision is pending, which could significantly impact cancer screening practices in the U.S.
QUESTION: How might the availability of a blood test for cancer detection change the way people approach their health and regular medical check-ups?
FDA panel endorses first-of-a-kind cancer blood test from Grail
